Table 3.
Ongoing clinical trials on TKIs for refractory ITP registered on clinicaltrials.gov.
| NCT | Drug | Phase | N | Population | Outcomes | End Date |
|---|---|---|---|---|---|---|
| Bruton tyrosine kinase and Janus kinase inhibitors | ||||||
| NCT04562766 | Rilzabrutinib | Phase III RCT | 224 | Persistent and chronic ITP | Efficacy and safety | 2025 |
| NCT05446831 | Baricitinib | Phase II | 33 | Steroid relapsed/refractory ITP | Efficacy/safety | 2023 |
| NCT05124028 | Orelabrutinib | Phase I/II | 10 | Primary ITP | Efficacy and safety | 2022 |
| NCT05020288 | Orelabrutinib | Phase II | 40 | Refractory ITP | Efficacy and safety | 2024 |
| NCT05232149 | Orelabrutinib | Phase II | 30 | Refractory ITP | Efficacy and safety | 2024 |
| NCT05279872 | Zanubrutinib | Phase I/II | 10 | Primary ITP | Efficacy and safety | 2022 |
| NCT05369377 | Zanubrutinib + eltrombopag | Open label, RCT, phase II | 150 | Refractory ITP | Efficacy and safety | 2025 |
| NCT05369364 | Zanubrutinib + Dexamethasone | Open label, RCT, phase II | 150 | First line ITP | Efficacy and safety | 2025 |
| Spleen tyrosine kinase inhibitors | ||||||
| NCT04056195 | SKI-O-703 | Phase II, RCT | 60 | Refractory ITP | Efficacy and safety | 2022 |
| NCT05509582 | Fostamatinib | Phase II | 20 | Post-transplant ITP | Efficacy and safety | 2028 |
| ITP = immune thrombocytopenia | ||||||